SEC Comment Letter 0000000000-24-014181 to Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899) (PTIX)
Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)
Date: Dec. 20, 2024 · CIK: 0001022899 · Accession: 0000000000-24-014181
AI Filing Summary & Sentiment
File numbers found in text: 333-283949
Letter
December 20, 2024 Garo Armen, Ph.D. Executive Chairman Protagenic Therapeutics, Inc. 149 Fifth Avenue, Suite 500 New York, NY 10010 Re:Protagenic Therapeutics, Inc. Registration Statement on Form S-1 Filed December 20, 2024 File No. 333-283949 Dear Garo Armen Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Kelly Carr, Esq.
Show Raw Text
December 20, 2024
Garo Armen, Ph.D.
Executive Chairman
Protagenic Therapeutics, Inc.
149 Fifth Avenue, Suite 500
New York, NY 10010
Re:Protagenic Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 20, 2024
File No. 333-283949
Dear Garo Armen Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Kelly Carr, Esq.